Sutimlimab生物类似药-研究级
货号：ICH5012-500mg
品牌：ichorbio
产品特性
英文名称: Sutimlimab Biosimilar - Research Grade
内毒素水平≤ 1.0 EU/mg
纯度：>95% by SDS-PAGE
应用: Functional Assays.
| 规格 | 价格 |
|---|---|
| 500mg | ￥咨询 |
产品咨询：info@biopcr.com
产品订购：sales@biopcr.com
技术支持：tech@biopcr.com
服务热线：400-860-6200
详细介绍
产品名称：Sutimlimab生物类似药-研究级
别名：Sutimlimab Biosimilar-Research Grade
应用：Functional Assays
亚型：Human IgG4
浓度：5mg/ml
反应性：Human
特异性：Detects human C1s. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sutimlimab.
存储溶液：Sterile, preservative-free, solution in PBS. BSA and Azide free.
储存条件：This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
推荐同型对照（Isotype Control）：Bulk Human IgG4 Isotype Control (IB4) [ICH2257]
推荐缓冲液（Buffer）：体内抗体缓冲液pH7.4
靶点（Target）: C1s
UniProt：P09871
纯化方法（Purification method）： This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
背景资料（Background）：RUO sutimlimab biosimilar is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in cold agglutinin disease to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways.
内毒素（Endotoxin）：≤ 1.0 EU/mg as determined by the LAL method
纯度（Purity）：>95% by SDS-PAGE
应用说明（Application Notes）：This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
产品使用（Use）：Products are for research use only. Not for use in diagnostic or therapeutic procedures.
运输条件：Blue ice
返回列表
推荐缓冲液（Buffer）：体内抗体缓冲液pH7.4
靶点（Target）: C1s
UniProt：P09871
纯化方法（Purification method）： This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
背景资料（Background）：RUO sutimlimab biosimilar is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in cold agglutinin disease to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways.
内毒素（Endotoxin）：≤ 1.0 EU/mg as determined by the LAL method
纯度（Purity）：>95% by SDS-PAGE
应用说明（Application Notes）：This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
产品使用（Use）：Products are for research use only. Not for use in diagnostic or therapeutic procedures.
运输条件：Blue ice
